Sage Theraputic RG (SAGE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sage Theraputic RG (SAGE)

SAGE 8.680

0.0%

Jul 31 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: Lynn	11/4/2018 7:38:58 PM
	of 16

FDA advisory committee back Sage's brexanolone for PPD Nov. 2, 2018 2:43 PM ET\| About: Sage Therapeutics (SAGE) By: Stephen Alpher, SA News Editor FDA advisors voted 18-0 that Zulresso (brexanolone) is effective for treatment of postpartum depression despite some reservations about the safety of home infusion. An FDA decision is expected by December 19. SAGE remains halted from trade. Previously: Sage Therapeutics shares halted pending Ad Com outcome (Nov. 2) Update: The vote was 17-1 that the drug's benefits outweigh the risks. seekingalpha.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext